NASDAQ:OCS Oculis (OCS) Stock Price, News & Analysis $7.61 -0.03 (-0.43%) Closing price 03:59 PM EasternExtended Trading$7.63 +0.02 (+0.30%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Oculis Stock (NASDAQ:OCS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oculis alerts:Sign Up Key Stats Today's Range$7.54▼$8.2150-Day Range$6.83▼$12.1752-Week Range$6.78▼$34.47Volume165,568 shsAverage Volume415,347 shsMarket Capitalization$441.08 millionP/E RatioN/ADividend YieldN/APrice Target$38.57Consensus RatingModerate Buy Company Overview Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide. Its therapies remain investigational, and the company’s work is centered on advancing candidates through clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Oculis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreOCS MarketRank™: 2.667682926825 of 5 starsOculis scored higher than 53% of companies evaluated by MarketBeat, and ranked 540th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingOculis has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOculis has a consensus price target of $38.57, representing about 406.2% upside from its current price of $7.62.Amount of Analyst CoverageOculis has only been the subject of 3 research reports in the past 90 days.Read more about Oculis' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oculis are expected to decrease in the coming year, from ($1.83) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oculis is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oculis is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOculis has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.73% of the float of Oculis has been sold short.Short Interest Ratio / Days to CoverOculis has a short interest ratio ("days to cover") of 5.64.Change versus previous monthShort interest in Oculis has recently decreased by 11.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOculis does not currently pay a dividend.Dividend GrowthOculis does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.56 News SentimentOculis has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Oculis this week, compared to 5 articles on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oculis insiders have not sold or bought any company stock.Percentage Held by Institutions22.30% of the stock of Oculis is held by institutions.Read more about Oculis' insider trading history. Receive OCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCS Stock News HeadlinesOculis Gets FDA Clearance To Advance Privosegtor In Acute Multiple Sclerosis Relapses3 hours ago | rttnews.comOculis Expands Privosegtor Into Multiple Sclerosis Following IND ClearanceNovember 16 at 7:45 AM | rttnews.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 16 at 1:00 AM | American Alternative (Ad)Oculis Announces FDA IND Clearance for Privosegtor in Acute MS RelapsesNovember 16 at 2:31 AM | quiverquant.comQOculis Gains FDA IND Clearance for Privosegtor in Acute MS RelapsesNovember 16 at 2:31 AM | quiverquant.comQOculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis RelapsesNovember 16 at 2:00 AM | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesNovember 13 at 4:05 PM | globenewswire.comOculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development PipelineNovember 9, 2026 | globenewswire.comSee More Headlines OCS Stock Analysis - Frequently Asked Questions How have OCS shares performed this year? Oculis' stock was trading at $19.97 at the start of the year. Since then, OCS stock has decreased by 61.8% and is now trading at $7.62. How were Oculis' earnings last quarter? Oculis Holding AG (NASDAQ:OCS) released its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.10. The business earned $8.38 thousand during the quarter, compared to analyst estimates of $260 thousand. Oculis had a negative net margin of 8,613.92% and a negative trailing twelve-month return on equity of 39.24%. Who are Oculis' major shareholders? Oculis' top institutional investors include Marshall Wace LLP (0.45%), Checkpoint Capital L.P. (0.17%), Alps Advisors Inc. (0.14%) and Aberdeen Group plc (0.12%). How do I buy shares of Oculis? Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oculis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oculis investors own include ARM (ARM), Broadcom (AVGO), CervoMed (CRVO), KLA (KLAC), Microchip Technology (MCHP), Marvell Technology (MRVL) and Micron Technology (MU). Company Calendar Last Earnings11/03/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 OCS's financial health is in the Red zone, according to TradeSmith. OCS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OCS CIK1953530 Webwww.oculis.com Phone41-21-711-3970FaxN/AEmployees60Year Founded2017Price Target and Rating Average Price Target for Oculis$38.57 High Price Target$55.00 Low Price Target$20.00 Potential Upside/Downside+407.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$119.44 million Net Margins-8,613.92% Pretax Margin-8,844.59% Return on Equity-39.24% Return on Assets-33.45% Debt Debt-to-Equity Ratio0.01 Current Ratio10.41 Quick Ratio10.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.08 per share Price / Book1.86Miscellaneous Outstanding Shares57,984,000Free FloatN/AMarket Cap$441.14 million OptionableOptionable Beta0.67 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:OCS) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.